Free shipping on all orders over $ 500

EPZ004777

Cat. No. M2334

All AbMole products are for research use only, cannot be used for human consumption.

EPZ004777 Structure
Size Price Availability Quantity
5mg USD 100  USD100 In stock
10mg USD 160  USD160 In stock
25mg USD 320  USD320 In stock
50mg USD 500  USD500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

EPZ004777 is a potent, selective, small-molecule inhibitor of DOT1L with IC50 of 0.4 nM. EPZ004777 selectively inhibits H3K79 methylation and blocks expression of leukemogenic genes. EPZ004777 suppressed expression of leukemogenic genes such as Hoxa cluster genes and Meis1, and selectively impaired proliferation of MLL-AF10 and CALM-AF10 transformed cells. In vivo administration of EPZ004777 leads to extension of survival in a mouse MLL xenograft model.

Customer Product Validations & Biological Datas
Source Cell Death Dis (2018). Figure 2. EPZ004777
Method Bone resorption assay
Cell Lines RAW264.7 cells
Concentrations 10 μM
Incubation Time 60 h
Results Furthermore, no significant difference was observed between the effects of treatment at 1 and 10 μM of the DOT1L inhibitors. In bone resorption assays, both EPZ5676 and EPZ004777 increased the resorption pit area at 1 and 10 μM concentrations
Chemical Information
Molecular Weight 539.67
Formula C28H41N7O4
CAS Number 1338466-77-5
Solubility (25°C) DMSO 100 mg/mL
Ethanol 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Deshpande AJ, et al. Blood. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

[2] Chen L, et al. Leukemia. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.

[3] Daigle SR, et al. Cancer Cell. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Related Histone Methyltransferase Products
WDR5-IN-4

WDR5-IN-4 is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity.

CMP-5 dihydrochloride

CMP-5 dihydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 dihydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations.

MS67 

MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM.

MS8511 

MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP).

TM2-115 

TM2-115 inhibits malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death.

  Catalog
Abmole Inhibitor Catalog




Keywords: EPZ004777 supplier, Histone Methyltransferase, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.